These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 3259039)

  • 1. Potentiation of immunosuppressive action of cyclosporine A by platelet-activating factor antagonists: an approach of the mechanism of action of these drugs in the prevention of graft rejection.
    Pignol B; Henane S; Pirotzky E; Mencia-Huerta JM; Braquet P
    Transplant Proc; 1988 Apr; 20(2 Suppl 2):259-65. PubMed ID: 3259039
    [No Abstract]   [Full Text] [Related]  

  • 2. Prolongation of cardiac allograft survival with BN 52021, a specific antagonist of platelet-activating factor.
    Foegh ML; Khirabadi BS; Rowles JR; Braquet P; Ramwell PW
    Transplantation; 1986 Jul; 42(1):86-8. PubMed ID: 3523888
    [No Abstract]   [Full Text] [Related]  

  • 3. In vitro effects of ginkgolide B combined with cyclosporin A on T-lymphocyte activation and IL-5 expression in peripheral blood mononuclear cells from asthmatic subjects.
    Mahmoud FF; Abul HT; Haines DD; Abal AT; Wise JA
    Transplant Proc; 2002 Nov; 34(7):2958-61. PubMed ID: 12431672
    [No Abstract]   [Full Text] [Related]  

  • 4. Platelet-activating factor in organ transplant rejection.
    Foegh ML; Chambers E; Khirabadi BS; Nakanishi T; Ramwell PW
    Adv Prostaglandin Thromboxane Leukot Res; 1989; 19():377-82. PubMed ID: 2526501
    [No Abstract]   [Full Text] [Related]  

  • 5. From ginkgolides to N-substituted piperidino-thieno diazepines, a new series of highly potent dual antagonists.
    Braquet P; Laurent JP; Rolland A; Martin C; Pommier J; Hosford D; Esanu A
    Adv Prostaglandin Thromboxane Leukot Res; 1991; 21B():929-37. PubMed ID: 1825436
    [No Abstract]   [Full Text] [Related]  

  • 6. [Renal diseases and platelet activating factor].
    Pirotzky E; Colliez P; Guilmard C; Braquet P
    Pediatrie; 1989; 44(3):163-7. PubMed ID: 2740184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of long-term treatment with platelet-activating factor on cytokine production by rat spleen cells.
    Pignol B; Hénane S; Mencia-Huerta JM; Braquet P
    Int Arch Allergy Appl Immunol; 1989; 88(1-2):161-3. PubMed ID: 2785086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proofs of involvement of PAF-acether in various immune disorders using BN 52021 (ginkgolide B): a powerful PAF-acether antagonist isolated from Ginkgo biloba L.
    Braquet P
    Adv Prostaglandin Thromboxane Leukot Res; 1986; 16():179-98. PubMed ID: 2949548
    [No Abstract]   [Full Text] [Related]  

  • 9. Inhibition of human lymphocyte proliferation and interleukin 2 production by platelet activating factor (PAF-acether): reversal by a specific antagonist, BN 52021.
    Rola-Pleszczynski M; Pignol B; Pouliot C; Braquet P
    Biochem Biophys Res Commun; 1987 Feb; 142(3):754-60. PubMed ID: 3493773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-anaphylactic properties of BN 52021: a potent platelet activating factor antagonist.
    Braquet P; Bourgain RH
    Adv Exp Med Biol; 1987; 215():215-35. PubMed ID: 3314403
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of long-term treatment with platelet-activating factor on IL-1 and IL-2 production by rat spleen cells.
    Pignol B; Hénane S; Sorlin B; Rola-Pleszczynski M; Mencia-Huerta JM; Braquet P
    J Immunol; 1990 Aug; 145(3):980-4. PubMed ID: 2373865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stimulus amplification by PAF and LTB4 in human neutrophils.
    Baggiolini M; Dewald B
    Pharmacol Res Commun; 1986 Aug; 18 Suppl():51-9. PubMed ID: 3022311
    [No Abstract]   [Full Text] [Related]  

  • 13. The synergism between platelet-activating factor and interleukin-1 on cartilage breakdown.
    Howat D; Desa F; Chander C; Moore A; Willoughby D
    J Lipid Mediat; 1990; 2 Suppl():S143-9. PubMed ID: 2133279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ginkgolides and platelet-activating factor binding sites.
    Hosford DJ; Domingo MT; Chabrier PE; Braquet P
    Methods Enzymol; 1990; 187():433-46. PubMed ID: 2172741
    [No Abstract]   [Full Text] [Related]  

  • 15. Cardiac electrophysiologic and ultrastructural effects of platelet-activating factor and its antagonist BN 52021.
    Kecskemeti V; Balogh I
    Transplant Proc; 1995 Oct; 27(5):2819-20. PubMed ID: 7482928
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of preservation/reperfusion injury by platelet-activating factor antagonism in the rat liver graft.
    Minor T; Yamaguchi T; Isselhard W
    Transplant Proc; 1995 Feb; 27(1):522-3. PubMed ID: 7879086
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of the platelet-activating factor antagonist BN 52021 on anti-islet cytotoxicity of mononuclear cells and serum from type 1 (insulin-dependent) diabetic patients.
    Köhler E; Varnai G; Knospe S; Förster W; Michaelis D; Wanka H
    Int Arch Allergy Appl Immunol; 1991; 95(4):352-5. PubMed ID: 1959976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet-activating factor antagonist BN52021 improves survival in normothermic liver ischemia in rats.
    Borobia FG; Figueras J; Escriba JM; Farran L; Rafecas A; Fabregat J; Torras J; Jaurrieta E
    Transplant Proc; 1993 Aug; 25(4):2543-4. PubMed ID: 8356661
    [No Abstract]   [Full Text] [Related]  

  • 19. [Phospholipid thrombocyte activating factor, its analogs and antagonists: prospects of their use in medicine].
    Kulikov VI; Muzia GI
    Vestn Akad Med Nauk SSSR; 1991; (10):13-7. PubMed ID: 1801455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Platelet-activating factor (PAF) antagonists].
    Terasawa M
    Tanpakushitsu Kakusan Koso; 1991 Feb; 36(3):379-87. PubMed ID: 1850862
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.